Trial Profile

Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apixaban (Primary)
Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism; Venous thrombosis
Focus Adverse reactions; Therapeutic Use
Acronyms CAP

Most Recent Events

03 Feb 2022 Results assessing the efficacy and safety of low-dose apixaban for 30 months, after initial six months of full-dose treatment, published in the Journal of Thrombosis and Haemostasis
24 Jun 2018 Status changed from recruiting to completed.
07 Jun 2016 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com